Concepts (48)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrologists | 1 | 2021 | 7 | 0.790 |
Why?
|
| Pediatricians | 1 | 2021 | 9 | 0.790 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2021 | 6 | 0.790 |
Why?
|
| Rheumatologists | 1 | 2021 | 14 | 0.780 |
Why?
|
| Remission Induction | 1 | 2021 | 111 | 0.770 |
Why?
|
| Edema | 1 | 2021 | 66 | 0.760 |
Why?
|
| Rituximab | 1 | 2021 | 61 | 0.760 |
Why?
|
| Sarcoidosis | 1 | 2021 | 77 | 0.740 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 193 | 0.690 |
Why?
|
| Dendritic Cells | 2 | 2012 | 201 | 0.620 |
Why?
|
| Immune Tolerance | 2 | 2012 | 114 | 0.460 |
Why?
|
| Plasma Cells | 1 | 2012 | 19 | 0.410 |
Why?
|
| Autoantibodies | 2 | 2012 | 434 | 0.400 |
Why?
|
| Stem Cells | 1 | 2012 | 248 | 0.360 |
Why?
|
| Interleukin-6 | 2 | 2012 | 330 | 0.350 |
Why?
|
| Macrophages | 1 | 2012 | 647 | 0.320 |
Why?
|
| Immunoglobulins | 1 | 2007 | 97 | 0.280 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2021 | 31 | 0.200 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 32 | 0.190 |
Why?
|
| Expert Testimony | 1 | 2021 | 47 | 0.190 |
Why?
|
| Antirheumatic Agents | 1 | 2021 | 59 | 0.190 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2007 | 756 | 0.180 |
Why?
|
| Consensus | 1 | 2021 | 211 | 0.180 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 109 | 0.180 |
Why?
|
| Child | 2 | 2021 | 6405 | 0.180 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2012 | 118 | 0.170 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 649 | 0.170 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2012 | 114 | 0.170 |
Why?
|
| Recurrence | 1 | 2021 | 948 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 442 | 0.150 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 1033 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 2791 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2800 | 0.110 |
Why?
|
| Radiation Chimera | 1 | 2012 | 15 | 0.100 |
Why?
|
| CD40 Ligand | 1 | 2012 | 14 | 0.100 |
Why?
|
| Antigens, Nuclear | 1 | 2012 | 24 | 0.100 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 100 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 217 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 626 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1692 | 0.080 |
Why?
|
| Mice | 2 | 2012 | 8474 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2673 | 0.070 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2007 | 89 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2007 | 432 | 0.060 |
Why?
|
| Humans | 2 | 2021 | 68618 | 0.060 |
Why?
|
| DNA | 1 | 2007 | 597 | 0.060 |
Why?
|
| Animals | 2 | 2012 | 20881 | 0.050 |
Why?
|
| Female | 1 | 2021 | 38074 | 0.040 |
Why?
|